Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Adynxx, Inc.
ClinicalTrials.gov Identifier:
NCT01731730
First received: November 19, 2012
Last updated: November 19, 2013
Last verified: November 2013

November 19, 2012
November 19, 2013
January 2013
October 2013   (final data collection date for primary outcome measure)
  • Pain with walking during 5 meter walk test [ Time Frame: 0-48 hours after surgery ] [ Designated as safety issue: No ]
    Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 5 meter walk test during inpatient stay 0-48 hours
  • Pain with walking during 15 meter walk test [ Time Frame: From hospital discharge to Day 28 ] [ Designated as safety issue: No ]
    Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 15 meter walk test during outpatient period up to Day 28
Same as current
Complete list of historical versions of study NCT01731730 on ClinicalTrials.gov Archive Site
  • Total use of opioid medications (morphine equivalents) during hospital stay [ Time Frame: 0-48 hours after surgery ] [ Designated as safety issue: No ]
  • Total use of opioid medications (morphine equivalents) post-discharge to Day 28 [ Time Frame: From hospital discharge to Day 28 ] [ Designated as safety issue: No ]
  • Pain with 45 degrees of knee flexion [ Time Frame: 0-48 hours after surgery ] [ Designated as safety issue: No ]
    Mean pain rating on the Numerical Rating Scale (NRS) for 45 degrees active knee flexion
  • Pain with 90 degrees of knee flexion [ Time Frame: From 7 to 28 days after surgery ] [ Designated as safety issue: No ]
    Mean pain rating on the Numerical Rating Scale (NRS) for 90 degrees active knee flexion
Same as current
Brief Pain Inventory functional interference scores at Days 7, 14, 21, 28, and 42 [ Time Frame: 7 to 42 days after surgery ] [ Designated as safety issue: No ]
Not Provided
 
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
Study to Evaluate the Safety & Efficacy of a Single Intrathecal Pre-Operative Administration of AYX1 Injection at Two Dose Levels Compared to Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty (TKA)

The objectives of this proof of concept study are to evaluate the safety and preventive analgesic efficacy of a single preoperative intrathecal administration of AYX1 Injection in patients undergoing unilateral total knee arthroplasty.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Postsurgical Pain
  • Drug: Placebo Injection
    3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
  • Drug: AYX1 Injection 110 mg
    3mL solution for intrathecal injection with 110 mg of AYX1
  • Drug: AYX1 Injection 330 mg
    3mL solution for intrathecal injection with 330 mg of AYX1
  • Placebo Comparator: Placebo (Vehicle) Injection
    Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
    Intervention: Drug: Placebo Injection
  • Experimental: AYX1 Injection 110 mg
    Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
    Intervention: Drug: AYX1 Injection 110 mg
  • Experimental: AYX1 Injection 330 mg
    Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
    Intervention: Drug: AYX1 Injection 330 mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
102
November 2013
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Scheduled to undergo primary unilateral TKA for painful osteoarthritis
  • American Society of Anesthesiologists Physical Status Classification System ≤ 3
  • Medically stable as determined by the Investigator based on pre-study medical history, physical/neurological examination, clinical lab tests, and 12-lead ECG findings
  • Body mass index of 18-40 kg/m2
  • Stable medical regimen for ≥ 1 month before randomization
  • Able to read and understand study instructions in English, and willing and able to comply with all study procedures

Exclusion Criteria:

  • More than 2 other current focal areas of pain, none greater in intensity than the target knee and no other active chronic pain conditions that would compromise operative knee pain evaluation
  • Inflammatory arthridities (i.e., rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis, gout)
  • Operative arthroscopy in the surgical knee in the last 6 months, or other prior surgery in either knee in the last 12 months, except for diagnostic arthroscopy
  • Planned use of any of the following for TKA: general endotracheal anesthesia (GETA), peripheral nerve block (i.e., femoral nerve block), neuroaxial (intrathecal or epidural) opioids postoperatively, or knee capsule injections
  • Received aspirin within 1 week of randomization, or any nonsteroidal anti-inflammatory drug (NSAID) within 5 half-lives prior to randomization, or planned use of NSAIDS post-operatively through Day 28
  • Use of more than 20 mg per day (on average) of oral morphine or its equivalent within 1 month prior to randomization
  • Use of adjuvant analgesics for chronic pain control (i.e., gabapentin, pregabalin) during the month prior to randomization or planned use post-operatively through Day 28
  • Daily use of benzodiazepines in the 3 months prior to randomization (unless used for sleep and dosage will be consistent after surgery)
  • Use of systemic corticosteroids (does not include inhaled steroids) within 3 months or intra-articular steroid injections within 1 month prior to randomization, or planned use of either post-op through Day 28
  • Treatment with antibiotics or antivirals (EXCEPTION: topical treatments), immunosuppressives, antipsychotics, anticholinergics, or anticonvulsants within 1 month of randomization, with the exception of prescribed pre-surgical prophylactic antibiotics, and aspirin for cardiac prophylaxis (as long as discontinued within 1 week of randomization
  • Current neurologic disorder, which could confound the assessment of pain (i.e., Parkinson's, Multiple Sclerosis)
  • Current active depression symptoms
  • Has had a change in dose or regimen of SSRIs or SNRIs for depression within 1 month of randomization
  • Mini Mental State Exam score < 24 at screening
  • Current history of insulin dependent diabetes mellitus, or autoimmune conditions
  • Severe chronic obstructive or restrictive pulmonary disease, current diagnosis of obstructive sleep apnea documented by a sleep laboratory study, or current home use of continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BIPAP)
  • Current evidence of alcohol abuse or history of alcohol-related complications within 1 year of randomization
  • Known or suspected history of illicit drug abuse within 1 year before randomization, current or planned use of medical marijuana, or history of opioid dependence within 2 years before randomization
  • Any malignancy within the past year, with the exception of basal cell carcinoma or uncomplicated or stable skin cancers documented to not require further or immediate treatment
  • Women who are pregnant or nursing
Both
40 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01731730
ADYX-002
Yes
Adynxx, Inc.
Adynxx, Inc.
Not Provided
Study Director: Donald C Manning, MD, PhD Adynxx, Inc.
Adynxx, Inc.
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP